The LNP-pE285K-mAb treatment markedly increased the number of tumor-infiltrating CD8_Naive, CD8_Tem, and CD8_Tex populations, supporting the anti-tumor activities of memory and exhausted CD8+ cytotoxic T cells. The gene discussed is CD8A; the disease is neoplasm.